Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Solé, Laura
- dc.contributor.author Lobo-Jarne, Teresa
- dc.contributor.author Cabré-Romans, Júlia-Jié
- dc.contributor.author González, Antón
- dc.contributor.author Fernández, Lierni
- dc.contributor.author Marruecos, Laura
- dc.contributor.author Guix Arnau, Marta, 1974-
- dc.contributor.author Cuatrecasas, Miriam
- dc.contributor.author López Prades, Sandra
- dc.contributor.author Bellosillo Paricio, Beatriz
- dc.contributor.author Torres, Ferran
- dc.contributor.author Iglesias Coma, Mar
- dc.contributor.author Bigas Salvans, Anna
- dc.contributor.author Espinosa Blay, Lluís
- dc.date.accessioned 2024-10-01T06:31:47Z
- dc.date.available 2024-10-01T06:31:47Z
- dc.date.issued 2024
- dc.description.abstract Background: We have previously shown that non-curative chemotherapy imposes fetal conversion and high metastatic capacity to cancer cells. From the set of genes differentially expressed in Chemotherapy Resistant Cells, we obtained a characteristic fetal intestinal cell signature that is present in a group of untreated tumors and is sufficient to predict patient prognosis. A feature of this fetal signature is the loss of CDX1. Methods: We have analyzed transcriptomic data in public datasets and performed immunohistochemistry analysis of paraffin embedded tumor samples from two cohorts of colorectal cancer patients. Results: We demonstrated that low levels of CDX1 are sufficient to identify patients with poorest outcome at the early tumor stages II and III. Presence tumor areas that are negative for CDX1 staining in stage I cancers is associated with tumor relapse. Conclusions: Our results reveal the actual possibility of incorporating CDX1 immunostaining as a valuable biomarker for CRC patients.
- dc.format.mimetype application/pdf
- dc.identifier.citation Solé L, Lobo-Jarne T, Cabré-Romans JJ, González A, Fernández L, Marruecos L, et al. Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients. Biochim Biophys Acta Mol Cell Res. 2024 Mar;1871(3):119658. DOI: 10.1016/j.bbamcr.2024.119658
- dc.identifier.doi http://dx.doi.org/10.1016/j.bbamcr.2024.119658
- dc.identifier.issn 0167-4889
- dc.identifier.uri http://hdl.handle.net/10230/61278
- dc.language.iso eng
- dc.publisher Elsevier
- dc.relation.ispartof Biochim Biophys Acta Mol Cell Res. 2024 Mar;1871(3):119658
- dc.rights © 2024 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
- dc.subject.keyword CDX1
- dc.subject.keyword Colorectal cancer
- dc.subject.keyword Fetal conversion
- dc.subject.keyword Patient prognosis
- dc.title Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion